Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

(2018) Jan Steffel et al.   EUROPEAN HEART JOURNAL

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

(2017) Jonathan AC Sterne et al.   HEALTH TECHNOLOGY ASSESSMENT

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

(2017) José A López-López et al.   BMJ-British Medical Journal

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis

(2017) José A López-López et al.   BMJ-British Medical Journal

Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation

(2016) Jennie Korenstra et al.   EUROPACE

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups

(2016) Gregory Y.H. Lip et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation

(2015) Gregory Y.H. Lip et al.   CLINICAL THERAPEUTICS

Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings

(2014) Talitha I. Verhoef et al.   American Journal of Cardiovascular Drugs

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

(2014) Gregory Y.H. Lip et al.   CLINICAL THERAPEUTICS

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands

(2014) Jelena Stevanović et al.   PLoS One

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

(2012) J Donald Easton et al.   LANCET NEUROLOGY

Catalogue of EQ-5D Scores for the United Kingdom

(2011) Patrick W. Sullivan et al.   MEDICAL DECISION MAKING

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The burden of atrial fibrillation in the Netherlands

(2011) H. E. Heemstra et al.   Netherlands Heart Journal

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage

(2008) Daniel O. Claassen et al.   ARCHIVES OF NEUROLOGY